Shots:

• The P-I trial involves assessing of DMB-3115 vs reference products (US- and EU-marketed products under the name of Stelara) in healthy volunteers to evaluate its safety- PK and tolerability in Europe
• In 2011- Meiji and Dong-A signed a joint venture agreement on biosimilars to build DM Bio Limited in Incheon Free Economic Zone and will manufacture DMB-3115
• DMB-3115 (biosimilar- ustekinumab) is a recombinant immunoglobulin G1 kappa mAb targeting interleukin (IL)-12 and IL-23 while the dosing started on Dec 13- 2019

Click here to read full press release/ article | Ref: Meiji | Image: Signbox